SCHEMBL2345762

SCHEMBL2345762

Cc1noc(NC(=O)N2CCC3(CC2)CC(c2cccc(C(F)(F)F)c2)C3)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.50
LMNA P02545 2/20 0.42
CCR2 P41597 1/20 0.41
EPHX2 P34913 1/20 0.41
CYP3A4 P08684 3/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP2D6 P10635 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 2/20 0.39
CHRM4 P08173 1/20 0.39
USP2 O75604 1/20 0.39
CYP2C9 P11712 1/20 0.39
GRIN2B Q13224 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2429562 0.88 MGLL (0.44) MGLLLMNACCR2MEN1MAPT
SCHEMBL2425659 0.88 MGLL (0.44) MGLLLMNACCR2MEN1MAPT
SCHEMBL2348397 0.88 MGLL (0.49) MGLLEPHX2CYP3A4ALDH1A1CYP2D6
SCHEMBL13355105 0.87 CYP3A4 (0.43) MGLLEPHX2CYP3A4ALDH1A1CYP2D6
SCHEMBL2341031 0.87 MGLL (0.52) MGLLEPHX2CYP3A4ALDH1A1CYP2D6
SCHEMBL2341595 0.86 CYP3A4 (0.42) MGLLEPHX2CYP3A4ALDH1A1CYP2D6
SCHEMBL2336329 0.85 CYP3A4 (0.47) MGLLLMNACYP3A4CYP2D6HTT
SCHEMBL2341906 0.85 CYP3A4 (0.44) CYP3A4ALDH1A1CYP2D6SMN1; SMN2CYP1A2
SCHEMBL2341768 0.85 MGLL (0.51) MGLLLMNACYP3A4ALDH1A1CYP2D6
SCHEMBL2342294 0.85 CYP3A4 (0.41) MGLLEPHX2CYP3A4ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358704-A1 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase Pfizer Inc. (US) 2011-08-24 EP claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US claimed
WO-2010049841-A1 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE PFIZER INC. (US) 2010-05-06 WO claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
WO-2010049841-A1 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE PFIZER INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS FAAH, FAAH2, APEH MGLL 298/4885LMNA 2680/4885CCR2 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.